[HTML][HTML] Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition
L Zimmer, U Hillen, E Livingstone… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
L Zimmer, U Hillen, E Livingstone, ME Lacouture, K Busam, RD Carvajal, F Egberts…
Journal of Clinical Oncology, 2012•ncbi.nlm.nih.govPurpose Selective inhibition of mutant BRAF by using class I RAF inhibitors in patients with
metastatic melanoma has resulted in impressive clinical activity. However, there is also
evidence that RAF inhibitors might induce carcinogenesis or promote tumor progression via
stimulation of MAPK signaling in RAF wild-type cells. We analyzed melanocytic lesions
arising under class I RAF inhibitor treatment for dignity, specific genetic mutations, or
expression of signal transduction molecules.
metastatic melanoma has resulted in impressive clinical activity. However, there is also
evidence that RAF inhibitors might induce carcinogenesis or promote tumor progression via
stimulation of MAPK signaling in RAF wild-type cells. We analyzed melanocytic lesions
arising under class I RAF inhibitor treatment for dignity, specific genetic mutations, or
expression of signal transduction molecules.
Abstract
Purpose
Selective inhibition of mutant BRAF by using class I RAF inhibitors in patients with metastatic melanoma has resulted in impressive clinical activity. However, there is also evidence that RAF inhibitors might induce carcinogenesis or promote tumor progression via stimulation of MAPK signaling in RAF wild-type cells. We analyzed melanocytic lesions arising under class I RAF inhibitor treatment for dignity, specific genetic mutations, or expression of signal transduction molecules.
ncbi.nlm.nih.gov